STUDY ABOUT ANTI-DEMENTIA DRUG USE IN PRIMARY CARE

被引:0
|
作者
Carracedo Martinez, Eduardo [1 ]
机构
[1] SERGAS, Area Sanit Santiago de Compostela, Santiago De Compostela, A Coruna, Spain
来源
ATENCION FARMACEUTICA | 2009年 / 11卷 / 02期
关键词
MEMANTINE; CHOLINESTERASE INHIBITORS; ALZHEIMER'S; PRIMARY CARE; ALZHEIMERS-DISEASE; MEMANTINE TREATMENT; CONTROLLED-TRIAL; DEMENTIA; MODERATE; PREVALENCE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To perform a study about the use of memantine and cholinesterase inhibitors (donepezil, galantamine and rivastigmine) in primary care. Method: Cross-sectional 3-month study in five primary care units from the Santiago de Compostela (A Coruna) Healthcare Area. Results: The prevalence in the use of anti-dementia drugs is 0.36% with a 95% confidence interval (CI 95%) of 0.27% to 0.45%. No active principle is more used than the others. 96% of patients suffer from Alzheimer and 4% of Parkinson's-related dementia. 25% of these patients use memantine together with a cholinesterase inhibitor Conclusions: There is a widespread use of anti-dementia drugs even if the cognitive benefits are not yet considered as of clinical relevance. As well, the proportion of patients that use together these two anti-dementia drugs is high even if the efficacy of such association is under question.
引用
收藏
页码:124 / 126
页数:3
相关论文
共 50 条
  • [31] Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials
    Rockwood, K
    MacKnight, C
    NEUROEPIDEMIOLOGY, 2001, 20 (02) : 51 - 56
  • [32] The anti-dementia drugs:: myth, hype or reality?
    Allain, H
    Bentué-Ferrer, D
    CURRENT OPINION IN NEUROLOGY, 2003, 16 : S23 - S27
  • [33] Persistence and Dose Escalation of Anti-dementia Medications
    Brewer, Linda
    Bennett, Kathleen
    Williams, David
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S222 - S222
  • [34] Do standard anti-dementia drug trial tests capture symptoms that are important to patients?
    Fay, S
    Rockwood, K
    NEUROBIOLOGY OF AGING, 2004, 25 : S325 - S325
  • [35] Persistence and Dose Escalation of Anti-Dementia Medications
    Brewer, Linda
    Bennett, Kathleen
    Williams, David
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S258 - S259
  • [36] Concomitant use of anti-dementia drugs with psychotropic drugs in Norway-a population-based study
    Langballe, Ellen Melbye
    Engdahl, Bo
    Selbk, Geir
    Nordeng, Hedvig
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (12) : 1319 - 1326
  • [37] Allocation ethical considerations as example of the anti-dementia
    Helmchen, Hanfried
    NERVENARZT, 2007, 78 : 404 - 404
  • [38] Anti-dementia effect of salvianolic acid B
    Zhang, Juntian
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 246P - 246P
  • [39] Antipsychotic Drug Prescribing to Patients on Anti-Dementia Drugs in a South African Patient Population
    Truter, Ilse
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 74 - 74
  • [40] A population-based study of dosing and persistence with anti-dementia medications
    Brewer, Linda
    Bennett, Kathleen
    McGreevy, Cora
    Williams, David
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (07) : 1467 - 1475